SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Planning commission supports 100% FDI in pharma sector

12 Jul 2011 Evaluate

Planning Commission deputy chairman Montek Singh Ahluwalia on July 11, authorized allowing 100% foreign direct investment (FDI) in the pharmaceutical sector. He said, 'I endorse the view that there should be no case for rollback from 100% FDI, while addressing a press conference.

Earlier, the Department of Industrial Policy and Promotion (DIPP), a nodal agency responsible for FDI-related matters, had also raised concerns over the growing dominance of multinationals in the sector. On the other hand, domestic pharma companies, headed by the Indian Drug Manufacturers Association and Indian Pharmaceutical Alliance, had also raised concerns that the takeover of Indian companies by foreign firms could lead to a situation of over-pricing of drugs and marginalization of homegrown firms.

To tackle the situation, an inter-ministerial panel comprising senior officials from the health ministry, department of industrial policy and promotion, the pharmaceuticals department and the finance ministry was tasked with the consent of suggesting measures that could help retain India's competitiveness. And the panel on July 5 recommended that the FDI cap for brown-field pharma projects, which would include expansion and mergers and acquisitions (M&As), be cut to 49%, while the ceiling for green-field ventures be retained at 100%.

'I don't think there is any move anywhere to prevent expansion of existing 100% foreign-owned pharmaceutical companies or green-field investment by foreign companies,' Ahluwalia said.

Following the inter-ministerial panel’s recommendation, the government had set up a group under Planning Commission member Arun Maira to look at the ideal policy regime for the sector. On this matter, deputy chairman said 'The expert group appointed under Arun Maira will see whether there is any problem relating to merger and acquisition rules of pharmaceutical companies in the country.'

In 2008, Japan's Daiichi Sankyo acquired a majority stake in Ranbaxy Laboratories, whereas in 2010, Abbott Laboratories acquired Piramal Healthcare’s domestic formulation business. With the growing dominance of MNCs into the sector, industrial organizations backed by domestic companies are seeking limitations on M&As arguing that India would turn into a contact manufacturing center and would lose its advantage, also other concern is that prices of medicines will increase due to lack of generics and rise of imported patented drugs.

In 2001, when the government issued a press note allowing 100% FDI under the automatic route, it had put in place two conditions related to transfer of technology and investment in manufacturing, said Indian Pharmaceutical Alliance secretary general D G Shah. "Both conditions have not been met. On the contrary, what we are seeing is several companies are shutting down manufacturing facilities in India, are winding up R&D and are importing patented medicines while not producing drugs or vaccines for the local market. If this continues, we will only be involved in contract manufacturing," he added.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Planning commission supports 100% FDI in pharma sector

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.